SLC2A1 and cancer: A peptide-based FOXM1 proteolysis-targeting chimera was reported to effectively enter cells and induce FOXM1 protein degradation, strongly inhibiting the viability, migration, and invasion of various cancer cell lines, reducing the expression levels of GLUT1 and the immune checkpoint PD-L1, and consequently decreasing glucose metabolism in cancer cells.